A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
Calvo V, Zheng W, Adam-Artigues A, Staschke K, Huang X, Cheung J, Nobre A, Fujisawa S, Liu D, Fumagalli M, Surguladze D, Stokes M, Nowacek A, Mulvihill M, Farias E, Aguirre-Ghiso J. A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells. Clinical Cancer Research 2023, 29: 5155-5172. PMID: 37982738, PMCID: PMC10842363, DOI: 10.1158/1078-0432.ccr-23-1427.Peer-Reviewed Original ResearchCancer cellsIntegrated stress responsePERK inhibitionRounds of therapyPERK inhibitorDormant cancer cellsQuiescent cancer cellsMicro-metastatic lesionsAnti-proliferative therapiesMetastasis biopsiesMetastatic burdenCDK4/6 inhibitorsPDX modelsSingle-cell gene expression profilingHER2 activityMetastatic progressionGene expression profilingSurvival factorUnresolved ER stressHigh expressionMouse syngeneicER stressMetastasisHER2Therapy